Literature DB >> 12946024

Pathological adhesion of primary human schwannoma cells is dependent on altered expression of integrins.

Tamara Utermark1, Katherine Kaempchen, C Oliver Hanemann.   

Abstract

Mutations in the tumor suppressor gene coding for merlin cause Neurofibromatosis type 2 (NF2), all spontaneous schwannomas, and a majority of meningiomas. Merlin links transmembrane proteins to the cytoskeleton. Accordingly, primary human schwannoma cells lacking merlin show an increased number of lamellipodia and filopodia as well as increased cell spreading. We show enhanced adhesion in primary human schwannoma cells and present evidence that this is dependent on the integrin chains alpha6beta1 and alpha6beta4. We further demonstrate that the integrin chains beta1 and beta4 are upregulated in schwannomas using different complementary methods, and report higher expression of these integrins per schwannoma cell by fluorescence assisted cell sorting (FACS). Finally we report clustering of the integrin chains alpha6, beta1, and beta4 on schwannoma cells. Our findings fit well into recent data on the role of merlin in signaling cascades connected to integrins and help explain pathological ensheathment of extracellular matrix or pseudomesaxon formation which is a hallmark of schwannoma histopathology.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12946024     DOI: 10.1111/j.1750-3639.2003.tb00034.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  12 in total

Review 1.  Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms.

Authors:  Steven L Carroll
Journal:  Acta Neuropathol       Date:  2011-12-11       Impact factor: 17.088

Review 2.  News on the genetics, epidemiology, medical care and translational research of Schwannomas.

Authors:  C O Hanemann; D G Evans
Journal:  J Neurol       Date:  2006-12       Impact factor: 4.849

3.  Cellular prion protein (PrPC) in the development of Merlin-deficient tumours.

Authors:  L Provenzano; Y Ryan; D A Hilton; J Lyons-Rimmer; F Dave; E A Maze; C L Adams; R Rigby-Jones; S Ammoun; C O Hanemann
Journal:  Oncogene       Date:  2017-07-10       Impact factor: 9.867

Review 4.  Emerging therapeutic targets in schwannomas and other merlin-deficient tumors.

Authors:  Sylwia Ammoun; C Oliver Hanemann
Journal:  Nat Rev Neurol       Date:  2011-06-07       Impact factor: 42.937

5.  Sensitive detection of deletions of one or more exons in the neurofibromatosis type 2 (NF2) gene by multiplexed gene dosage polymerase chain reaction.

Authors:  Ruth Diebold; Britta Bartelt-Kirbach; D Gareth Evans; Dieter Kaufmann; C Oliver Hanemann
Journal:  J Mol Diagn       Date:  2005-02       Impact factor: 5.568

6.  An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis.

Authors:  Dina S Stepanova; Galina Semenova; Yin-Ming Kuo; Andrew J Andrews; Sylwia Ammoun; C Oliver Hanemann; Jonathan Chernoff
Journal:  Cancer Res       Date:  2017-07-20       Impact factor: 12.701

7.  PAK kinase regulates Rac GTPase and is a potential target in human schwannomas.

Authors:  Christine Flaiz; Jonathan Chernoff; Sylwia Ammoun; Jeffrey R Peterson; Clemens O Hanemann
Journal:  Exp Neurol       Date:  2009-05-03       Impact factor: 5.330

8.  The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours.

Authors:  Sylwia Ammoun; Marei Caroline Schmid; Lu Zhou; David A Hilton; Magdalena Barczyk; Clemens Oliver Hanemann
Journal:  Mol Oncol       Date:  2014-08-27       Impact factor: 6.603

9.  A proteasome-resistant fragment of NIK mediates oncogenic NF-κB signaling in schwannomas.

Authors:  Jeffrey R Gehlhausen; Eric Hawley; Benjamin Mark Wahle; Yongzheng He; Donna Edwards; Steven D Rhodes; Jacquelyn D Lajiness; Karl Staser; Shi Chen; Xianlin Yang; Jin Yuan; Xiaohong Li; Li Jiang; Abbi Smith; Waylan Bessler; George Sandusky; Anat Stemmer-Rachamimov; Timothy J Stuhlmiller; Steven P Angus; Gary L Johnson; Grzegorz Nalepa; Charles W Yates; D Wade Clapp; Su-Jung Park
Journal:  Hum Mol Genet       Date:  2019-02-15       Impact factor: 6.150

10.  The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.

Authors:  L Zhou; J Lyons-Rimmer; S Ammoun; J Müller; E Lasonder; V Sharma; E Ercolano; D Hilton; I Taiwo; M Barczyk; C O Hanemann
Journal:  Oncogene       Date:  2015-11-09       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.